Impact of lifetime psychiatric diagnosis on long-term retention and survival of former opiate addicts in methadone maintenance treatment

References

• Abramsohn Y, Peles E, Potik D, Schreiber S, Adelsom M. 2009. Sense of coherence as a stable predictor for methadone maintenance treatment (MMT) outcome. J Psychoactive Drugs 41:249–253.
   PubMed Web of Science ®Google Scholar
• Brooner RK, King VL, Kidorf M, Schmidt CW Jr, Bigelow GE. 1997. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 54:71–80.
   PubMed Web of Science ®Google Scholar
• Cacciola JS, Alterman AI, Rutherford MJ, McKay JR, Mulvaney FD. 2001. The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug Alcohol Depend 61:271–280.
   PubMed Web of Science ®Google Scholar
• Calia R, Lai C, Aceto P, Luciani M, Saraceni C, Avolio AW, et al. 2011. Psychological risk factors for graft rejection among liver transplant recipients. Transplant Proc 43:1123–1127.
   PubMedGoogle Scholar
• Callaly T, Trauer T, Munro L, Whelan G. 2001. Prevalence of psychiatric disorder in a methadone maintenance population. Aust NZ J Psychiatry 35:601–605.
   PubMed Web of Science ®Google Scholar
• Dean L, Falsetti SA. 2013. Treating patients with borderline personality disorder in the medical office. Am Fam Physician 88:140–141.
   PubMedGoogle Scholar
• Gelkopf M, Weizman T, Melamed Y, Adelson M, Bleich A. 2006. Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an Israeli methadone maintenance clinic. Isr J Psychiatry Relat Sci 43:126–136.
   PubMed Web of Science ®Google Scholar
• Grella CE, Karno MP, Warda US, Niv N, Moore AA. 2009. Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict Behav 34:498–504.
   PubMed Web of Science ®Google Scholar
• Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, et al. 2004. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend 75:37–45.
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. 1960. J Neurol Neurosurg Psychiatry 23:56–61.
   PubMed Web of Science ®Google Scholar
• Hawks RL. 1986. NIDA Res Monogr 73:30–42.
   PubMedGoogle Scholar
• Maremmani AG, Rovai L, Bacciardi S, Rugani F, Pacini M, Paolo Pani P, et al. 2013. The long-term outcomes of heroin dependent-treatment-resistant patients with bipolar 1 comorbidity after admission to enhanced methadone maintenance. J Affect Disord 151:582–589.
   PubMed Web of Science ®Google Scholar
• Maremmani I, Pacini M, Lubrano S, Perugi G, Tagliamonte A, Pani PP, et al. 2008. Long-term outcomes of treatment-resistant heroin addicts with and without DSM-IV axis I psychiatric comorbidity (dual diagnosis). Eur Addict Res 14:134–142.
   PubMed Web of Science ®Google Scholar
• Maremmani I, Zolesi O, Aglietti M, Tagliamonte A, Shinderman M, Maxwell S. 2000. Methadone dose and retention during treatment of heroin addicts with Axis I psychiatric comorbidity. J Addict Dis 19:29–41.
   PubMed Web of Science ®Google Scholar
• McLellan AT, Luborsky L, O’Brien CP, Barr HL, Evans F. 1984. The Addiction Severity Index in three different populations. NIDA Research Monograph 55:217–223.
   PubMedGoogle Scholar
• Newton-Howes G, Tyrer P, Johnson T, Mulder R, Kool S, Dekker J, et al. 2014. Influence of personality on the outcome of treatment in depression: systematic review and meta- analysis. J Pers Disord. 28:577–593.
   PubMedGoogle Scholar
• Overall JE, Gorham DR. 1988. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacology Bulletin 24:97–99.
   Web of Science ®Google Scholar
• Pani PP, Maremmani I, Pacini M, Lamanna F, Maremmani AG, Dell'osso L. 2011. Effect of psychiatric severity on the outcome of methadone maintenance treatment. Eur Addict Res 17:80–89.
   PubMed Web of Science ®Google Scholar
• Palmer NB, Salcedo J, Miller AL, Winiarski M, Arno P. 2003. Psychiatric and social barriers to HIV medication adherence in a triply diagnosed methadone population. AIDS Patient Care STDS 17:635–644.
   PubMed Web of Science ®Google Scholar
• Peles E, Linzy S, Kreek M, Adelson M. 2008. One-year and cumulative retention as predictors of success in methadone maintenance treatment: a comparison of two clinics in the United States and Israel. J Addict Dis 27:11–25.
   PubMed Web of Science ®Google Scholar
• Peles E, Schreiber S, Adelson M. 2010. 15-Year survival and retention of patients in a general hospital-affiliated methadone maintenance treatment (MMT) center in Israel. Drug Alcohol Depend 107:141–148.
   PubMed Web of Science ®Google Scholar
• Perini G, Grigoletti L, Hanife B, Biggeri A, Tansella M, Amaddeo F. 2013. Cancer mortality among psychiatric patients treated in a community-based system of care: a 25-year case register study. Soc Psychiatry Psychiatr Epidemiol. 49:693–701.
   PubMedGoogle Scholar
• Potik D, Adelson, M, Schreiber S. 2007. Drug addiction from a psychodynamic perspective: methadone maintenance treatment (MMT) as Transitional Phenomena. Psychol Psychother: Theory Res Pract 80:311–325.
   PubMed Web of Science ®Google Scholar
• Potik D, Abramsohn Y, Peles E, Schreiber S, Adelson M. 2011. Working in the conflict-free sphere: adaptation group in methadone maintenance treatment (MMT). J Groups Addict Recov 6:285–306.
   Google Scholar
• Potik D, Peles E, Abramsohn Y, Adelson M, Schreiber S. 2014. The Relation between vulnerable attachment style, psychopathology, drug abuse and retention in treatment among methadone maintenance treatment patients. J Psychoactive Drugs doi: 10.1080/02791072.2014.944290 (accepted for publication).
   PubMedGoogle Scholar
• Ross J, Teesson M, Darke S, Lynskey M, Ali R, Ritter A, et al. 2005. The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev 24:411–418.
   PubMed Web of Science ®Google Scholar
• Salamina G, Diecidue R, Vigna-Taglianti F, Jarre P, Schifano P, Bargagli AM, et al. 2010. VEdeTTE Study Group. Effectiveness of therapies for heroin addiction in retaining patients in treatment: results from the VEdeTTE study. Subst Use Misuse 45:2076–2092.
   PubMed Web of Science ®Google Scholar
• Samuels J. 2011. Personality disorders: epidemiology and public health issues. Int Rev Psychiatry 23:223–233.
   PubMed Web of Science ®Google Scholar
• Samuels J, Eaton WW, Bienvenu OJ III, Brown CH, Costa PT Jr, Nestadt, G. 2002. Prevalence and correlates of personality disorders in a community sample. Br J Psychiatry 180:536–542.
   PubMed Web of Science ®Google Scholar
• Shalev AY, Sahar T, Abramovitz M. 1996. Hebrew version: SCID (DSM-IV) structured clinical interview for Axis I DSM-IV disorders, SCID-I/P (V. 2.0), Patient Version. Department of Psychiatry, Hadassah University Hospital, PO Box 12000, Jerusalem, Israel.
   Google Scholar
• Van Der Kolk BA, Spinazzola J, Blaustein ME, Hopper JW, Hopper EK, Korn DL, et al. 2007. A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. J Clin Psychiatry 68:37–46.
   PubMed Web of Science ®Google Scholar
• Wedekind D, Jacobs S, Karg I, Luedecke C, Schneider U, Cimander K, et al. 2010. Psychiatric comorbidity and additional abuse of drugs in maintenance treatment with L- and D,L-methadone. World J Biol Psychiatry 11:390–399.
   PubMed Web of Science ®Google Scholar